iBio Doses First Participant in 32-Patient IBIO-600 Phase 1 Obesity Trial
IBIO•iBio has dosed the first participant in a randomized, placebo-controlled, single ascending dose Phase 1 trial of IBIO-600 in 32 adults with overweight or obesity. In non-human primates IBIO-600 demonstrated a 40–52 day half-life and up to 5.1% lean mass gain with fat mass reductions, supporting potential for infrequent dosing.
1. Phase 1 Trial Initiation
iBio has initiated its first-in-human Phase 1 trial by dosing the first participant in a randomized, placebo-controlled, single ascending dose study of IBIO-600 in adults with overweight or obesity. The trial plans to enroll approximately 32 individuals who will be monitored for safety, tolerability, pharmacokinetics and pharmacodynamics over nine months, with completion expected in the second half of 2027.
2. Preclinical Profile and Efficacy
In non-human primate studies, a single administration of IBIO-600 achieved a half-life of 40–52 days, supporting a long-acting dosing regimen. The therapy produced up to 5.1% lean mass gains and concurrent fat mass reductions, highlighting its potential to preserve muscle and improve body composition during weight loss.
3. Clinical-Stage Transition and Pipeline Outlook
With the dosing milestone, iBio has transitioned into a clinical-stage biotechnology company. The company anticipates advancing its second obesity asset, IBIO-610, into clinical trials in the first half of 2027, reflecting the speed of its AI-driven discovery platform.
